Showing results (171-180 of 190) with videos related to
Sort By:
Pageof 19
Circulation|July 1, 1997
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic InvestigatorsR Q Migrino, J B Young, S G Ellis, et al.Journal of the American College of Cardiology|October 1, 1989
Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study GroupE J Topol, S G Ellis, R M Califf, et al.The American Journal of Cardiology|March 1, 1993
Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomyJ J Popma, N B De Cesare, C A Pinkerton, et al.Circulation|August 1, 1991
Relation of stenosis morphology and clinical presentation to the procedural results of directional coronary atherectomyS G Ellis, N B De Cesare, C A Pinkerton, et al.Journal of the American College of Cardiology|November 11, 1991
Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomyJ J Popma, N B De Cesare, S G Ellis, et al.Circulation|April 15, 1995
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT InvestigatorsJ E Tcheng, R A Harrington, K Kottke-Marchant, et al.Circulation|May 1, 1991
Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study GroupR M Califf, E J Topol, R S Stack, et al.Circulation|October 3, 2001
Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patientsW A Tan, H Tamai, S J Park, et al.JAMA|August 13, 1997
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic ComplicationE J Topol, J J Ferguson, H F Weisman, et al.Circulation|July 6, 2000
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesionsF A Cura, D L Bhatt, A M Lincoff, et al.Pageof 19